Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

RemeGen

HKEX: 09995 ↗~HK$55B MCAP

China-based biopharmaceutical company co-founded in 2008 and headquartered in Yantai, developing novel biologics and antibody-drug conjugates. Its marketed products include telitacicept for autoimmune disease and disitamab vedotin for HER2-expressing solid tumors.

Company Info

Sector:Biologics / Antibody-Drug Conjugates
Headquarters:Yantai, Shandong, China
Founded:2008

Clinical Development Pipeline

telitacicept (RC18)

Target: BAFF / APRIL
Systemic lupus erythematosus
Preclinical
Phase 1
Phase 2
Phase 3
Approved

disitamab vedotin (RC48)

Target: HER2
HER2-expressing solid tumors
Preclinical
Phase 1
Phase 2
Phase 3
Approved

RC148

Target: PD-1 / VEGF
AGA-negative non-squamous NSCLC, first line
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

No recent news updates available for this company.

Leadership Team

Dr. Jianmin Fang

Co-Founder, Chief Executive Officer and Chief Scientific Officer

Wang Weidong

Co-Founder

Dr. Daotian Fu

President

Careers & Job Openings

See all open roles

Multiple Departments
Yantai, Shandong, China
Apply Now →